Attaining LDL-cholesterol target post major coronary event: Care gap, associated factors and clinical outcomes - 30/04/26
, Meng Lu, MD, MS a, Alan S. Go, MD a, Jamal S. Rana, MD, PhD b, Karry Ngai, MD c, Adam M. Rogers, MD dHighlights |
• | Total 67% of patients attained LDL-C target at 1 year; 59% women and 54% African-Americans did. |
• | Average LDL-C post MACE was associated with subsequent ASCVD and composite CVD. |
• | Attaining LDL-C target predicted 21% and 16% lower risk of subsequent ASCVD and composite CVD, respectively. |
ABSTRACT |
Background |
Despite evidence supporting low-density lipoprotein cholesterol (LDL-C) reduction below 70 mg/dL after a major acute coronary event (MACE), many patients fail to reach this target.
Methods |
Retrospective cohort study (baseline 2012-2022) with follow-up through 12/31/2024 (median follow-up: 5.1 years). Participants were 47,416 adults with nonfatal myocardial infarction and/or coronary revascularization discharged on lipid-lowering therapy. Main exposures were LDL-C levels within 1-year postevent and annually for 10 years. Outcomes were incident ASCVD events (myocardial infarction, revascularization, ischemic stroke, CHD death) and composite CVD events (ASCVD, heart failure, peripheral vascular disease, CVD death).
Results |
The cohort's mean (SD) age was 66 (12) years; 72% were male, and 58% white. In year 1, 12% lacked LDL-C testing; this rose from 44% in year 2% to 64% in year 10. Target LDL-C attainment was 67% in year 1 and 57% to 60% in years 2 to 10. Women and African American patients had lower target attainment. There was a clear upward trend of improved target control over time (58% in 2012, 77% in 2022). Comorbidities, cardiac rehabilitation participation, and adherence to lipid lowering therapy were associated with improved LDL-C control. Achieving LDL-C < 70 mg/dL was associated with lower risk of ASCVD (HR 0.79, 95% CI: 0.77-0.82) and composite CVD (HR 0.84, 95% CI: 0.82-0.87); both P < .001. Numbers needed to treat (NNT) to prevent one ASCVD or composite CVD event were 19.7 and 26.3, respectively.
Conclusions |
Significant gaps exist in LDL-C monitoring and treatment goal attainment post-MACE. Notable disparities by sex and race/ethnicity were observed. Failure to meet LDL-C targets was associated with a significant increase in ASCVD and CVD risk.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Plan
| Journal Subject Terms: Low density lipoprotein cholesterol, target, secondary prevention. |
Vol 297
Article 107430- juillet 2026 Retour au numéro
Article précédent
- Assessment of the gradient gap after TAVR with balloon and self-expandable valves: Analysis of a large patient cohort
- Ziad Arow, Omar Oliva, Shahin Sanchez Seyeddi, Laurent Bonfils, Laurent Lepage, Rawia Hussein-Aro, Hana Vaknin-Assa, Abid Assali, Chiara De Biase, Didier Tchetche, Nicolas Dumonteil
- Outcomes of implantable cardioverter-defibrillator implantation in adults with congenitally corrected transposition of great arteries
- Alexander C. Egbe, Zeyad Kholeif, Malini Madhavan, Abhishek J. Deshmukh, Christopher V. DeSimone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?